("Amneal" or the "Company"), a global pharmaceutical company, today announced the advancement of two key strategic initiatives. First, the Company has resubmitted to the U.S. Food and Drug ...

Amneal Pharmaceuticals (NASDAQ:AMRX) has received FDA approval for its generic version of the GLP-1 agonist diabetes drug Byetta and resubmitted its New Drug Application for a prefilled syringe ...

TEVAN.UL] failed to convince a U.S. appeals court on Friday to reverse a decision that would remove patents related to its ...

On December 20th, 2024, the Court of Appeals for the Federal Circuit issued an important decision in Teva Branded ...

Amneal Pharmaceuticals (AMRX) announced the advancement of two key strategic initiatives. First, the Company has resubmitted to the U.S. Food and Drug Administration (FDA) its new drug application ...

On Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) reported third-quarter adjusted EPS of $0.16, down from $0.19 a year ago, beating the consensus of $0.14. The company reported sales of $702.47 ...

BRIDGEWATER, N.J., November 21, 2024--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist BRIDGEWATER ...

In an order posted by the U.S. Court of Appeals for the Federal Circuit, the court affirmed a win for Amneal Pharmaceuticals (AMRX) in a ...

Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts Amneal Pharmaceuticals Q3 sales rose 13% to $702.47 million, beating estimates. EPS hit $0.16, above consensus ...